ARWR - Arrowhead Pharmaceuticals, Inc. - SEC Form 4 Insider Trading Screener
94 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
| P | 11 | +3 | +5 | +4 | -5 |
| S | 35 | +0 | +0 | -1 | -24 |
X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2020-01-21 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $49.44 | -40,313 | 384,223 | -9% | -$1,992,925 | |||||
2020-01-06 | ARWR | Given Bruce D | COO | S - Sale | $60.13 | -35,613 | 858,993 | -4% | -$2,141,285 | ||||||
2020-01-06 | ARWR | O'Brien Patrick | GC | S - Sale | $60.12 | -14,625 | 258,375 | -5% | -$879,261 | ||||||
2020-01-06 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $60.11 | -20,000 | 391,185 | -5% | -$1,202,201 | ||||||
2019-12-24 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $63.50 | -83,333 | 1,805,237 | -4% | -$5,291,646 | ||||||
| M | 2019-12-12 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $67.15 | -183,333 | 1,888,570 | -9% | -$12,310,119 | |||||
| M | 2019-12-02 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $67.33 | -50,000 | 2,071,903 | -2% | -$3,366,522 | |||||
| D | 2019-11-01 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $40.85 | -37,884 | 313,536 | -11% | -$1,547,378 | |||||
| D | 2019-10-10 | ARWR | Anzalone Christopher Richard | CEO | S - Sale+OE | $31.83 | -56,325 | 2,121,903 | -3% | -$1,792,825 | |||||
2019-09-25 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $28.25 | -20,000 | 2,121,903 | -1% | -$565,000 | ||||||
| DM | 2019-09-20 | ARWR | Anzalone Christopher Richard | CEO | S - Sale+OE | $28.54 | -112,650 | 2,141,903 | -5% | -$3,215,055 | |||||
| M | 2019-09-09 | ARWR | Perry Michael S | Dir | S - Sale | $29.41 | -185,000 | 36,000 | -84% | -$5,440,000 | |||||
2019-06-26 | ARWR | Ferrari Mauro | Dir | S - Sale | $27.61 | -17,756 | 1,900 | -90% | -$490,243 | ||||||
2019-05-28 | ARWR | O'Brien Patrick | GC | S - Sale | $24.88 | -30,000 | 203,000 | -13% | -$746,400 | ||||||
2019-05-21 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $22.00 | -27,071 | 278,536 | -9% | -$595,562 | ||||||
2019-04-03 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $19.30 | -50,000 | 2,092,455 | -2% | -$965,000 | ||||||
| D | 2019-03-01 | ARWR | Given Bruce D | COO | S - Sale+OE | $19.99 | -42,500 | 644,606 | -6% | -$849,575 | |||||
| D | 2019-02-25 | ARWR | Given Bruce D | COO | S - Sale+OE | $18.98 | -42,500 | 644,606 | -6% | -$806,650 | |||||
| D | 2019-02-19 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $18.00 | -8,000 | 305,607 | -3% | -$144,000 | |||||
| DM | 2019-02-15 | ARWR | Given Bruce D | COO | S - Sale+OE | $17.86 | -68,750 | 644,606 | -10% | -$1,227,988 | |||||
| DM | 2019-02-08 | ARWR | Given Bruce D | COO | S - Sale+OE | $16.04 | -242,834 | 670,856 | -27% | -$3,894,247 | |||||
2019-02-05 | ARWR | Given Bruce D | COO | S - Sale | $14.48 | -22,500 | 847,856 | -3% | -$325,800 | ||||||
2019-02-01 | ARWR | Given Bruce D | COO | S - Sale | $13.85 | -28,500 | 870,356 | -3% | -$394,725 | ||||||
| M | 2019-01-22 | ARWR | Given Bruce D | COO | S - Sale | $13.54 | -169,500 | 898,856 | -16% | -$2,295,805 | |||||
2019-01-22 | ARWR | Given Douglas B | Dir | S - Sale | $13.58 | -3,000 | 178,130 | -2% | -$40,740 | ||||||
2019-01-18 | ARWR | O'Brien Patrick | GC | S - Sale | $14.43 | -72,000 | 233,000 | -24% | -$1,038,960 | ||||||
2019-01-17 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $14.55 | -81,875 | 305,607 | -21% | -$1,191,281 | ||||||
2019-01-14 | ARWR | Li Zhen | Snr. VP, Chem, Non-Clin Dev | S - Sale | $14.34 | -40,500 | 201,700 | -17% | -$580,770 | ||||||
| D | 2019-01-14 | ARWR | Given Bruce D | COO | S - Sale+OE | $14.40 | -42,666 | 1,068,356 | -4% | -$614,390 | |||||
2019-01-11 | ARWR | Waddill William D. | Dir | S - Sale | $14.77 | -8,500 | 46,500 | -15% | -$125,545 | ||||||
2019-01-02 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $11.98 | -8,333 | 387,482 | -2% | -$99,829 | ||||||
2019-01-02 | ARWR | Given Bruce D | COO | S - Sale | $11.98 | -20,000 | 1,098,356 | -2% | -$239,600 | ||||||
2018-12-27 | ARWR | Given Douglas B | Dir | S - Sale | $12.00 | -3,000 | 145,130 | -2% | -$36,000 | ||||||
2018-12-19 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $13.92 | -90,000 | 1,542,455 | -6% | -$1,252,800 | ||||||
2018-12-12 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $14.07 | -90,000 | 1,632,455 | -5% | -$1,266,300 | ||||||
2018-11-23 | ARWR | Given Douglas B | Dir | S - Sale | $12.74 | -3,000 | 148,130 | -2% | -$38,220 | ||||||
2018-11-09 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $14.39 | -81,500 | 1,722,455 | -5% | -$1,172,705 | ||||||
| D | 2018-10-19 | ARWR | Leone Peter Brian | VP, Strategic Bus. Initiatives | S - Sale+OE | $13.49 | -131,137 | 130,000 | -50% | -$1,769,038 | |||||
| D | 2018-09-06 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $19.34 | -45,000 | 310,815 | -13% | -$870,200 | |||||
| M | 2018-08-31 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $14.45 | -164,834 | 1,803,955 | -8% | -$2,381,851 | |||||
| D | 2018-06-19 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $14.01 | -20,000 | 310,815 | -6% | -$280,200 | |||||
| DM | 2018-05-30 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $11.00 | -14,000 | 310,815 | -4% | -$154,000 | |||||
2018-04-24 | ARWR | Given Douglas B | Dir | S - Sale | $6.63 | -25,000 | 155,000 | -14% | -$165,750 | ||||||
| D | 2018-03-27 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $8.00 | -20,000 | 310,815 | -6% | -$160,000 | |||||
2018-03-16 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $7.40 | -26,000 | 1,968,789 | -1% | -$192,400 | ||||||
| M | 2018-03-13 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $7.43 | -300,000 | 1,994,789 | -13% | -$2,228,000 | |||||
2018-03-05 | ARWR | Given Bruce D | COO | S - Sale | $6.73 | -20,000 | 908,356 | -2% | -$134,600 | ||||||
2018-01-01 | ARWR | Given Bruce D | COO | S - Sale | $3.69 | -20,000 | 928,356 | -2% | -$73,800 | ||||||
2016-10-14 | ARWR | Given Douglas B | Dir | S - Sale | $6.72 | -12,000 | 70,000 | -15% | -$80,640 | 0 | -1 | -29 | -78 | ||
| ADM | 2016-08-22 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $8.00 | -20,000 | 115,689 | -15% | -$160,000 | -1 | +2 | +1 | -67 | |
| DM | 2016-08-22 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $8.00 | -20,000 | 115,689 | -15% | -$160,000 | 0 | +2 | +4 | -59 | |
| D | 2015-12-30 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $6.13 | -23,347 | 135,000 | -15% | -$143,117 | -2 | -10 | -44 | -8 | |
| M | 2013-10-09 | ARWR | Ferrari Mauro | Dir | P - Purchase | $6.44 | +2,300 | 4,251 | +118% | +$14,808 | -2 | +1 | -3 | +2 | |
| D | 2015-01-05 | ARWR | Lewis David L. | Chief Scientific Officer | S - Sale+OE | $8.01 | -15,000 | 0 | -100% | -$120,104 | +8 | -15 | -10 | -12 | |
| A | 2014-10-15 | ARWR | Anzalone Christopher Richard | Pres, CEO | P - Purchase | $6.32 | +16,000 | 260,173 | +7% | +$101,120 | +8 | +5 | +1 | +10 | |
2014-10-15 | ARWR | Anzalone Christopher Richard | Pres, CEO | P - Purchase | $6.32 | +16,000 | 260,173 | +7% | +$101,120 | +8 | +5 | +1 | +10 | ||
| D | 2014-10-01 | ARWR | McKenney Charles | Dir | S - Sale+OE | $14.70 | -2,500 | 17,220 | -13% | -$36,749 | +1 | -8 | -48 | -43 | |
| D | 2014-09-30 | ARWR | Lewis David L. | Chief Scientific Officer | S - Sale+OE | $15.02 | -15,000 | 0 | -100% | -$225,350 | -7 | -9 | -52 | -53 | |
| D | 2014-09-26 | ARWR | Given Douglas B | Dir | S - Sale+OE | $15.24 | -2,000 | 20,000 | -9% | -$30,480 | -7 | -9 | -52 | -53 | |
| D | 2014-08-15 | ARWR | Given Douglas B | Dir | S - Sale+OE | $13.90 | -5,000 | 20,000 | -20% | -$69,501 | -4 | -5 | +13 | -49 | |
| D | 2014-08-15 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $14.02 | -40,000 | 71,500 | -36% | -$560,860 | -4 | -5 | +13 | -49 | |
| D | 2014-06-09 | ARWR | McKenney Charles | Dir | S - Sale+OE | $14.32 | -22,000 | 17,220 | -56% | -$315,005 | 0 | -10 | -18 | -63 | |
| D | 2014-02-12 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $18.77 | -16,000 | 71,500 | -18% | -$300,290 | +3 | +10 | +21 | -33 | |
| D | 2014-02-07 | ARWR | Frykman Edward W | Dir | S - Sale+OE | $15.98 | -3,148 | 23,852 | -12% | -$50,296 | +5 | +6 | +42 | -30 | |
| D | 2014-01-02 | ARWR | Lewis David L. | Chief Scientific Officer | S - Sale+OE | $10.29 | -15,000 | 0 | -100% | -$154,292 | +1 | +21 | +46 | +24 | |
2010-08-31 | ARWR | Anzalone Christopher Richard | Pres, CEO | P - Purchase | $0.89 | +10,000 | 341,729 | +3% | +$8,900 | +6 | +10 | +13 | -28 | ||
2010-08-27 | ARWR | Anzalone Christopher Richard | Pres, CEO | P - Purchase | $0.89 | +10,000 | 331,729 | +3% | +$8,900 | +1 | +15 | +13 | -25 | ||
2010-08-27 | ARWR | Myszkowski Kenneth Allen | CFO | P - Purchase | $0.89 | +15,000 | 15,000 | New | +$13,350 | +1 | +15 | +13 | -25 | ||
| D | 2008-08-22 | ARWR | Anzalone Christopher Richard | Pres, CEO | P - Purchase | $0.00 | +164,000 | 164,000 | New | +$0 | +8 | +7 | -3 | -72 | |
2007-12-05 | ARWR | McKenney Charles | Dir | S - Sale | $3.86 | -1,000 | 10,200 | -9% | -$3,860 | +1 | -6 | -16 | -46 | ||
2007-11-05 | ARWR | McKenney Charles | Dir | S - Sale | $3.91 | -1,000 | 11,200 | -8% | -$3,910 | +2 | +14 | +1 | -38 | ||
2007-10-05 | ARWR | McKenney Charles | Dir | S - Sale | $5.00 | -1,000 | 12,200 | -8% | -$5,000 | 0 | +1 | -22 | -41 | ||
2007-09-05 | ARWR | McKenney Charles | Dir | S - Sale | $5.04 | -1,000 | 13,200 | -7% | -$5,040 | -1 | -2 | -2 | -57 | ||
2007-08-06 | ARWR | McKenney Charles | Dir | S - Sale | $5.44 | -1,000 | 14,200 | -7% | -$5,440 | +2 | -2 | -2 | -47 | ||
2007-07-05 | ARWR | McKenney Charles | Dir | S - Sale | $4.88 | -1,000 | 15,200 | -6% | -$4,880 | -2 | +1 | +5 | -32 | ||
2007-06-05 | ARWR | McKenney Charles | Dir | S - Sale | $7.21 | -1,000 | 16,200 | -6% | -$7,210 | -4 | -8 | -33 | -46 | ||
2007-05-07 | ARWR | McKenney Charles | Dir | S - Sale | $7.00 | -1,000 | 17,200 | -5% | -$7,000 | -10 | -10 | +3 | -45 | ||
2007-04-05 | ARWR | McKenney Charles | Dir | S - Sale | $4.58 | -1,000 | 18,200 | -5% | -$4,576 | +2 | +11 | +51 | +2 | ||
2007-03-21 | ARWR | Knott David M | 10% | S - Sale | $3.80 | -1,410,950 | 2,703,259 | -34% | -$5,365,043 | +15 | +13 | +57 | +30 | ||
2007-03-19 | ARWR | Knott David M | 10% | S - Sale | $3.93 | -9,940 | 4,114,209 | 0% | -$39,064 | +5 | +21 | +43 | +27 | ||
2007-03-16 | ARWR | Knott David M | 10% | S - Sale | $4.11 | -27,682 | 4,124,149 | -1% | -$113,654 | -1 | +19 | +36 | +26 | ||
2007-03-05 | ARWR | McKenney Charles | Dir | S - Sale | $3.75 | -1,000 | 19,200 | -5% | -$3,750 | 0 | -1 | +28 | +33 | ||
2007-02-20 | ARWR | McKenney Charles | Dir | S - Sale | $3.98 | -500 | 20,200 | -2% | -$1,990 | -1 | -1 | +17 | +28 | ||
2007-02-05 | ARWR | McKenney Charles | Dir | S - Sale | $4.04 | -500 | 20,700 | -2% | -$2,020 | 0 | 0 | -10 | +28 | ||
| A | 2006-08-16 | ARWR | Knott David M | 10% | P - Purchase | $4.88 | +102,250 | 2,615,531 | +4% | +$498,980 | 0 | -3 | -6 | +10 | |
2007-01-22 | ARWR | McKenney Charles | Dir | S - Sale | $4.01 | -500 | 21,200 | -2% | -$2,005 | +3 | +8 | +3 | +12 | ||
2007-01-16 | ARWR | McKenney Charles | Dir | S - Sale | $4.01 | -500 | 21,700 | -2% | -$2,005 | -3 | -10 | -3 | +12 | ||
2007-01-10 | ARWR | Kingsley Joseph Theodore III | Interim Pres, CFO | P - Purchase | $4.18 | +2,000 | 12,000 | +20% | +$8,353 | +1 | +2 | +2 | +29 | ||
2006-08-16 | ARWR | Knott David M | 10% | P - Purchase | $4.88 | +102,250 | 2,615,531 | +4% | +$498,980 | +2 | -1 | -3 | -16 | ||
2005-05-19 | ARWR | Kingsley Joseph Theodore III | CFO | P - Purchase | $2.62 | +10,000 | 10,000 | New | +$26,191 | 0 | -3 | +11 | +52 | ||
2005-04-21 | ARWR | Ching Marshall Robert | 10% | S - Sale | $3.27 | -600,000 | 1,066,821 | -36% | -$1,962,000 | -7 | -18 | -24 | -11 | ||
| M | 2004-12-23 | ARWR | Ching Marshall Robert | 10% | S - Sale | $4.51 | -46,000 | 175,248 | -21% | -$207,578 | -2 | -6 | -23 | -35 | |
| M | 2004-12-20 | ARWR | Ching Marshall Robert | 10% | S - Sale | $4.44 | -67,000 | 221,248 | -23% | -$297,565 | +6 | +4 | -10 | -30 | |
2004-12-17 | ARWR | Ching Marshall Robert | 10% | S - Sale | $4.43 | -23,000 | 288,248 | -7% | -$101,959 | +3 | +7 | -7 | -33 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |